<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4197">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01278394</url>
  </required_header>
  <id_info>
    <org_study_id>AN2690-ONYC-201 Cohort 3</org_study_id>
    <nct_id>NCT01278394</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Subjects With Onychomycosis of the Great Toenail</brief_title>
  <official_title>An Open-Label, Rising Multiple-Dose, Multi-Center Study to Evaluate the Safety and Efficacy of Topically Applied AN2690 5.0% and 7.5% Solution for the Treatment of Adult Subjects With Onychomycosis of the Great Toenail</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anacor Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Anacor Pharmaceuticals, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Mexico: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine the safety and efficacy of 5.0% AN2690 Solution in
      the treatment of distal, subungual onychomycosis of the great target toenail.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this cohort, only the targeted great toenail identified at Baseline prior to the
      commencement of treatment from culture results collected at the Screening visit were
      evaluated for primary efficacy whereas all treated toenails were evaluated for safety. At
      each visit, the investigator was asked to make a clinical evaluation of the targeted great
      nail, marking whether or not they considered the nail to be clear of onychomycosis. This
      evaluation was the basis for determining whether or not study medication should be dispensed
      at the visit.

      This record includes information only for Cohort 3 (5% solution) of the study. Cohorts 1 and
      2, are described in NCT00679523 (7.5% solution). No comparison was made between Cohorts 1&amp;2
      and Cohort 3.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Clinical Evidence of Complete Clearance of the Treatment-targeted Great Toenail Plus a Negative Fungal Culture at Day 360</measure>
    <time_frame>Day 360</time_frame>
    <safety_issue>No</safety_issue>
    <description>Proportion of subjects with a clinical assessment of a clear (completely normal) nail unit plus a negative fungal culture from the treatment-targeted toenail at Day 360.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clear Nail Growth of the Targeted Toenail</measure>
    <time_frame>Day 360</time_frame>
    <safety_issue>No</safety_issue>
    <description>Clear nail was measured on digital images as the distance in millimeters from the proximal nail fold to the proximal limit of the disease as marked by the Investigator. New Clear Nail Growth (CNG) was calculated from the clear nail measurements.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mycological Evaluations (Negative Potassium Hydroxide (KOH) and Negative Fungal Culture) Compared to Baseline</measure>
    <time_frame>Day 90</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of subjects with negative KOH, and number of subjects with negative fungal cultures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mycological Evaluations (Negative KOH and Negative Fungal Culture) Compared to Baseline</measure>
    <time_frame>Day 180</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of subjects with negative KOH, and number of subjects with negative fungal cultures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mycological Evaluations (Negative KOH and Negative Fungal Culture) Compared to Baseline</measure>
    <time_frame>Day 270</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of subjects with negative KOH, and number of subjects with negative fungal cultures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mycological Evaluations (Negative KOH and Negative Fungal Culture) Compared to Baseline</measure>
    <time_frame>Day 360</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of subjects with negative KOH, and number of subjects with negative fungal cultures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Time to Clinical Evaluation of Clear or at Least 5 mm of CNG</measure>
    <time_frame>Baseline to 360</time_frame>
    <safety_issue>No</safety_issue>
    <description>Length of time to clinical evaluation of clear or at least 5 mm of CNG.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Onychomycosis</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AN2690 Solution, 5.0%</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AN2690 Solution, 5.0%</intervention_name>
    <description>Once daily application for 360 days</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects must meet all of the following criteria to be included in the study:

          2. Witnessed, signed informed consent approved by Ethics Committee.

          3. Male or female subjects of any race at least 18 years of age but not older than 65
             years of age at the time of screening.

          4. For Cohorts 1 and 2, subjects with a diagnosis of onychomycosis of at least one great
             toenail and with a positive KOH wet mount from that nail. For Cohort 3, subjects must
             have a diagnosis of onychomycosis of at least one great toenail and a positive KOH
             wet mount AND fungal culture from that nail.

          5. Onychomycosis involving 20-60% of the affected great toenail as determined by visual
             inspection after the nail has been trimmed.

          6. The combined thickness of the distal nail plate and the associated hyperkeratotic
             nail bed &lt;3 mm.

          7. Affected great toenail to be treated is capable of re-growth as documented by history
             or recent observation of at least 2 mm of growth.

          8. Normal or not clinically significant screening safety labs.

        Exclusion Criteria:

          1. Females of childbearing potential not using a highly effective method of birth
             control (e.g. implants, injectables, combined oral contraceptives, some intrauterine
             contraceptive devices) during the study.

          2. Diabetes mellitus requiring treatment other than diet and exercise.

          3. Subjects with chronic moccasin type of T. pedis.

          4. Subjects with a history of having failed any previous topical antifungal therapy for
             their onychomycosis.

          5. Subjects unwilling to refrain from the use of nail cosmetics such as clear and or
             colored nail lacquers from the screening visit until the end of the study.

          6. Subjects that have not undergone the specified washout period(s) for the following
             topical preparations or subjects who require the concurrent use of any of the
             following topical medications:

               -  Topical antifungal applied to the feet (does not include antifungals for
                  treatment of T. pedis during the study): 4 weeks

               -  Anti-inflammatories, corticosteroids, topical immunomodulators: 2 weeks

          7. Subjects that have not undergone the specified washout period(s) for the following
             systemic medications or subjects who require the concurrent use of any of the
             following systemic medications:

               -  Corticosteroids (including intramuscular injections): 2 weeks

               -  Antifungals for treatment of onychomycosis or any systemic antifungal with known
                  activity against dermatophytes: 24 weeks

               -  Systemic immunomodulators: 4 weeks

          8. Treatment of any type for cancer within the last 6 months.

          9. History of any significant internal disease.

         10. Subjects with a medical history of current or past psoriasis of the skin and/or
             nails.

         11. Concurrent lichen planus.

         12. Subjects who are known to be allergic to any of the test product(s) or any components
             in the test product(s) or history of hypersensitivity or allergic reactions to any of
             the study preparations as described in the Investigator's Brochure.

         13. Nail or anatomic abnormalities of the toe, e.g., genetic nail disorders, primentary
             disorders, onychogryphosis, trauma to the nail(s) to be treated.

         14. AIDS or AIDS related complex.

         15. History of street drug or alcohol abuse.

         16. Any subject not able to meet the study attendance requirements.

         17. Subjects who have participated in any other trial of an investigational drug or
             device within 60 days prior to enrollment or participation in a research study
             concurrent with this study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karl Beutner, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Anacor Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto Dermatologico Jalisciense</name>
      <address>
        <city>Guadalajara</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IMIC</name>
      <address>
        <city>Mexico City</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <lastchanged_date>July 25, 2014</lastchanged_date>
  <firstreceived_date>January 14, 2011</firstreceived_date>
  <firstreceived_results_date>July 25, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Onychomycosis</keyword>
  <keyword>Fungal Nail</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Onychomycosis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were screened and enrolled and two investigative sites in Mexico. The study population included men and women of any race, 18-65 years of age who had distal, subungual onychomycosis of the great toenail. The first subject visit occurred on March 28, 2007, and the last subject visit occurred on July 11, 2008.</recruitment_details>
      <pre_assignment_details>All subjects in Cohort 3 were treated with 5.0% AN2690 Solution.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>AN2690 Solution, 5.0%</title>
          <description>AN2690 Solution, 5.0%: Once daily application for 360 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All analyses were performed using the intent-to-treat (ITT) population.</population>
      <group_list>
        <group group_id="B1">
          <title>AN2690 Solution, 5.0%</title>
          <description>AN2690 Solution, 5.0%: Once daily application for 360 days</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="29"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="29"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="11"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="18"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Hispanic or Latino</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="29"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Not Hispanic or Latino</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Mexico</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="29"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="46.9" spread="10.15"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinical Evidence of Complete Clearance of the Treatment-targeted Great Toenail Plus a Negative Fungal Culture at Day 360</title>
        <description>Proportion of subjects with a clinical assessment of a clear (completely normal) nail unit plus a negative fungal culture from the treatment-targeted toenail at Day 360.</description>
        <time_frame>Day 360</time_frame>
        <safety_issue>No</safety_issue>
        <population>Efficacy data were analyzed for the ITT population. For efficacy variables, the last observation was carried forward (LOCF) to impute missing observations.</population>
        <group_list>
          <group group_id="O1">
            <title>AN2690 Solution, 5.0%</title>
            <description>AN2690 Solution, 5.0%: Once daily application for 360 days</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="29"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Clinical Evidence of Complete Clearance of the Treatment-targeted Great Toenail Plus a Negative Fungal Culture at Day 360</title>
            <description>Proportion of subjects with a clinical assessment of a clear (completely normal) nail unit plus a negative fungal culture from the treatment-targeted toenail at Day 360.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Success</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2" lower_limit="0.0" upper_limit="16.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Failure</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="27"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clear Nail Growth of the Targeted Toenail</title>
        <description>Clear nail was measured on digital images as the distance in millimeters from the proximal nail fold to the proximal limit of the disease as marked by the Investigator. New Clear Nail Growth (CNG) was calculated from the clear nail measurements.</description>
        <time_frame>Day 360</time_frame>
        <safety_issue>No</safety_issue>
        <population>Efficacy data were analyzed for the ITT population. For efficacy variables, the LOCF was used to impute missing observations.</population>
        <group_list>
          <group group_id="O1">
            <title>AN2690 Solution, 5.0%</title>
            <description>AN2690 Solution, 5.0%: Once daily application for 360 days</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="29"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Clear Nail Growth of the Targeted Toenail</title>
            <description>Clear nail was measured on digital images as the distance in millimeters from the proximal nail fold to the proximal limit of the disease as marked by the Investigator. New Clear Nail Growth (CNG) was calculated from the clear nail measurements.</description>
            <units>millimeters</units>
            <param>Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.5" lower_limit="-0.8" upper_limit="1.9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mycological Evaluations (Negative Potassium Hydroxide (KOH) and Negative Fungal Culture) Compared to Baseline</title>
        <description>Number of subjects with negative KOH, and number of subjects with negative fungal cultures.</description>
        <time_frame>Day 90</time_frame>
        <safety_issue>No</safety_issue>
        <population>Efficacy data were analyzed for the ITT population. For efficacy variables, the LOCF was used to impute missing observations.</population>
        <group_list>
          <group group_id="O1">
            <title>AN2690 Solution, 5.0%</title>
            <description>AN2690 Solution, 5.0%: Once daily application for 360 days</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="29"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mycological Evaluations (Negative Potassium Hydroxide (KOH) and Negative Fungal Culture) Compared to Baseline</title>
            <description>Number of subjects with negative KOH, and number of subjects with negative fungal cultures.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Fungal Culture Result Positive</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fungal Culture Result Negative</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="28" lower_limit="89.9" upper_limit="100"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>KOH Result Positive</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>KOH Result Negative</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5" lower_limit="3.5" upper_limit="31.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mycological Evaluations (Negative KOH and Negative Fungal Culture) Compared to Baseline</title>
        <description>Number of subjects with negative KOH, and number of subjects with negative fungal cultures.</description>
        <time_frame>Day 180</time_frame>
        <safety_issue>No</safety_issue>
        <population>Efficacy data were analyzed for the ITT population. For efficacy variables, the LOCF was used to impute missing observations.</population>
        <group_list>
          <group group_id="O1">
            <title>AN2690 Solution, 5.0%</title>
            <description>AN2690 Solution, 5.0%: Once daily application for 360 days</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="29"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mycological Evaluations (Negative KOH and Negative Fungal Culture) Compared to Baseline</title>
            <description>Number of subjects with negative KOH, and number of subjects with negative fungal cultures.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Fungal Culture Result Positive</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fungal Culture Result Negative</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="29" lower_limit="100" upper_limit="100"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>KOH Result Positive</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>KOH Result Negative</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9" lower_limit="14.2" upper_limit="47.9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mycological Evaluations (Negative KOH and Negative Fungal Culture) Compared to Baseline</title>
        <description>Number of subjects with negative KOH, and number of subjects with negative fungal cultures.</description>
        <time_frame>Day 270</time_frame>
        <safety_issue>No</safety_issue>
        <population>Efficacy data were analyzed for the ITT population. For efficacy variables, the LOCF was used to impute missing observations.</population>
        <group_list>
          <group group_id="O1">
            <title>AN2690 Solution, 5.0%</title>
            <description>AN2690 Solution, 5.0%: Once daily application for 360 days</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="29"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mycological Evaluations (Negative KOH and Negative Fungal Culture) Compared to Baseline</title>
            <description>Number of subjects with negative KOH, and number of subjects with negative fungal cultures.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Fungal Culture Result Positive</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fungal Culture Result Negative</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="28" lower_limit="89.9" upper_limit="100"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>KOH Result Positive</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>KOH Result Negative</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12" lower_limit="23.5" upper_limit="59.3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mycological Evaluations (Negative KOH and Negative Fungal Culture) Compared to Baseline</title>
        <description>Number of subjects with negative KOH, and number of subjects with negative fungal cultures.</description>
        <time_frame>Day 360</time_frame>
        <safety_issue>No</safety_issue>
        <population>Efficacy data were analyzed for the ITT population. For efficacy variables, the LOCF was used to impute missing observations.</population>
        <group_list>
          <group group_id="O1">
            <title>AN2690 Solution, 5.0%</title>
            <description>AN2690 Solution, 5.0%: Once daily application for 360 days</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="29"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mycological Evaluations (Negative KOH and Negative Fungal Culture) Compared to Baseline</title>
            <description>Number of subjects with negative KOH, and number of subjects with negative fungal cultures.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Fungal Culture Result Positive</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fungal Culture Result Negative</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="28" lower_limit="89.9" upper_limit="100"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>KOH Result Positive</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="23"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>KOH Result Negative</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6" lower_limit="5.9" upper_limit="35.4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Time to Clinical Evaluation of Clear or at Least 5 mm of CNG</title>
        <description>Length of time to clinical evaluation of clear or at least 5 mm of CNG.</description>
        <time_frame>Baseline to 360</time_frame>
        <safety_issue>No</safety_issue>
        <population>Efficacy data were analyzed for the ITT population. For efficacy variables, the LOCF was used to impute missing observations.</population>
        <group_list>
          <group group_id="O1">
            <title>AN2690 Solution, 5.0%</title>
            <description>AN2690 Solution, 5.0%: Once daily application for 360 days</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="29"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Length of Time to Clinical Evaluation of Clear or at Least 5 mm of CNG</title>
            <description>Length of time to clinical evaluation of clear or at least 5 mm of CNG.</description>
            <units>days</units>
            <param>Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="138.0" lower_limit="81.5" upper_limit="194"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Pre and post treatment to Day 360</time_frame>
      <desc>AEs were defined as any change (expected or unexpected) in a subject's medical health that occurred during the study. A serious AE was fatal, life-threatening, resulted in persistent or significant disability or incapacity, required or prolonged inpatient hospitalization, was a congenital anomaly, or another medically important condition.</desc>
      <group_list>
        <group group_id="E1">
          <title>AN2690 Solution, 5.0%</title>
          <description>AN2690 Solution, 5.0%: Once daily application for 360 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MeDRA 9.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Uterine haemorrhage (unrelated)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MeDRA 9.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Tinea pedis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood glucose abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Polycystic ovaries</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Ingrowing nail</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Onychomadesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Tooth extraction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Institution or Principal Investigator may only publish Study results after: (i) the results of the multicenter Study in its entirety have been publicly disclosed by the Sponsor in an abstract, manuscript or presentation form, or (ii) two (2) years after conclusion of the Study at all sites, whichever is first to occur.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sheryl Baldwin, RN/Associate Director</name_or_title>
      <organization>Anacor Pharmaceuticals, Inc.</organization>
      <phone>650-223-8597</phone>
      <email>clinicaltrials@anacor.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
